Immunohistochemical categorisation of ductal carcinoma in situ of the breast

British Journal of Cancer

Volumn 98, Issue 1, 2008, Pages 137-142

  Meijnen, P ^a   Peterse, J L ^a   Antonini, N ^a   Rutgers, E J Th ^a   Van De Vijver, M J ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Ductal carcinoma in situ (DCIS); Immunohistochemistry; Tissue microarray; Tumour classification

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CA 125 ANTIGEN; CD31 ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; SOMATOMEDIN; UVOMORULIN;

ADULT; AGED; ARTICLE; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; TISSUE MICROARRAY; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; BREAST NEOPLASMS; CA-125 ANTIGEN; CADHERINS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38049051926     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604112     Document Type: Article

References (21)

1. Baqai T, Shousha S (2003) Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast. Histopathology 42: 440-447
2. Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ (2005) Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg 92: 429-434
3. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative group and EORTC Radiotherapy Group. J Clin Oncol 24: 3381-3387
4. Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basallike phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19: 617- 621
5. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334
6. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ (2006) Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 8: R61
7. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180
8. Hoogerbrugge N, Bult P, Widt-Lever LM, Beex LV, Kiemeney LV, Ligtenberg MJ, Massuger LF, Boetes C, Manders P, Brunner HG (2003) High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21: 41-45
9. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38: 197-204
10. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100: 5974-5979
11. Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB (2004) Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10: 6143-6151
12. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98: 703-711
13. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
14. Ravdin PM, Chamness GC (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 159: 19-27
15. Rody A, Diallo R, Poremba C, Wuelfing P, Kissler S, Solbach C, Kaufmann M, Jackisch C (2005) Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor. Appl Immunohistochem Mol Morphol 13: 25-29
16. Selim AG, El Ayat G, Wells CA (2002) Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol 55: 14-16
17. Siziopikou KP, Prioleau JE, Harris JR, Schnitt SJ (1996) bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 77: 499-506
18. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Bussolati G, Coleman D, Connolly CE, Dervan P, Eusebi V, de Miguel C, Drijkoningen M, Elston CW, Faverley D, Gad A, Jacquemier J, Lacerda M, Martinez-Penuela J, Munt C, Peterse JL, Rank F, Sylvan M, Tsakraklides V, Zafrani B (1998) Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology. Hum Pathol 29: 1056-1062
19. Tsuda HH (2001) Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer. Breast Cancer 8: 38-44
20. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, van't Veer LJ (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65: 9155-9158
21. World Health Organization Classification of Tumours (2003) Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press